Skip to main content

NEUROPACE, INC. INVESTIGATION: NPCE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

The law firm of Kirby McInerney LLP is investigating potential claims against NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired NeuroPace securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to learn more about your rights.

[LEARN MORE ABOUT POTENTIAL SECURITIES FRAUD CLAIMS]

What Happened?

On November 13, 2026, NeuroPace released its third quarter 2026 financial results, announcing third quarter revenue of $23.1 million, a 1.1% decline year-over-year, and cutting its full year 2026 revenue guidance to $91 million to $92 million, down from $99.5 million to $101.5 million. NeuroPace CEO Joel Becker stated, “Our third quarter results fell short of our expectations,” attributing those results to “local operational issues” (such as staffing, physician availability, and diagnostic procedure capacity) at “several of our largest accounts,” as well as sales force disruption and the continued impact of the Company’s exit from the stereoelectroencephalography (“SEEG”) distribution business. Just three months earlier, on August 11, 2026, NeuroPace increased its full-year 2026 revenue guidance to $99.5 million to $101.5 million, up from $99 million to $101 million. In August, CFO Patrick Williams stated, “The increase in total revenue guidance reflects improved visibility into service revenue, which we now expect to be approximately $1 million for the full year, up from previous guidance of $500,000… We expect our third quarter RNS revenue growth to be similar to our first half RNS growth rate of approximately 20% year-over-year.” On the November news, the price of NeuroPace shares declined by $4.46 per share, or approximately 37.1%, from $12.02 per share on November 12, 2026 to close at $7.56 on November 13, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired NeuroPace securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT YOUR RIGHTS AS AN INVESTOR]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found on Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  267.74
+9.85 (3.82%)
AAPL  352.45
+0.54 (0.15%)
AMD  530.14
+26.73 (5.31%)
BAC  48.91
-0.53 (-1.07%)
GOOG  279.20
+1.60 (0.58%)
META  616.38
-2.49 (-0.40%)
MSFT  508.29
+2.05 (0.40%)
NVDA  150.96
-4.50 (-2.89%)
ORCL  113.89
-1.11 (-0.97%)
TSLA  383.72
+3.61 (0.95%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.